Anna Spreafico
University Health Network · 710 works · 9,658 citations · h-index 46
Top works
- Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer
- Sensitive tumour detection and classification using plasma cell-free DNA methylomes
- The Prognostic and Predictive Role of Histology in Advanced Non-small Cell Lung Cancer: A Literature Review
- Mass Spectrometry to Classify Non–Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study
- Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
- Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib
- A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer
- Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
- Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities
- Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.
- Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
- Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC).
- The postcoital IUD as an effective continuing contraceptive method
- Genomic testing in cancer: Patient knowledge, attitudes, and expectations
- Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer.
- Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
- Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022
- Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)
- Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma
- Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K- ras –Mutated Colorectal Cancer